Data-Driven Drug Trials: SEQSTER and Praxis Deepen CNS Partnership

ORLANDO, FL – February 02, 2026 – Amid the buzz of the SCOPE Summit for clinical trial innovation, healthcare technology leader SEQSTER and biopharmaceutical firm Praxis Precision Medicines today announced a significant expansion of their partnership. The collaboration aims to accelerate the development of crucial new treatments for Central Nervous System (CNS) disorders by leveraging a sophisticated data platform to streamline clinical trials, a move that signals a broader shift in how life-altering therapies are brought to market.

This expanded alliance will see SEQSTER's patient data orchestration platform integrated more deeply into Praxis's clinical programs, most notably its comprehensive ENERGY program for epilepsy. The announcement builds on a previously successful collaboration and highlights a growing industry trend: the fusion of advanced technology with precision neuroscience to tackle some of medicine's most complex challenges.

A Partnership Forged in Success

The decision to broaden the partnership was not made in a vacuum. It follows the resounding success of the initial collaboration on Praxis’s Essential3 Program for Essential Tremor, a debilitating neurological condition affecting an estimated seven million people in the United States. This program, which utilized SEQSTER’s platform, led to a landmark achievement: the first-ever positive Phase 3 results for a drug, ulixacaltamide, designed specifically for essential tremor.

The Essential3 trials demonstrated statistically significant improvements in both tremor control and patients' ability to perform daily activities. The innovative trial design was a key factor in this success. By implementing a home-based model, the program was able to engage a broad and diverse population across all 50 states, allowing participants to complete study visits from the comfort of their homes. SEQSTER's technology was instrumental in this patient-centric approach, enabling the seamless and secure collection of longitudinal health data required for the study.

Praxis is now preparing a New Drug Application (NDA) for ulixacaltamide, with a submission planned for early 2026. The efficiency and positive outcomes of this initial venture provided a powerful proof-of-concept, validating the strategic value of integrating a robust data platform into the core of clinical development.

“SEQSTER has been a foundational element of our clinical trial execution, enabling more efficient trial enrollment while capturing the longitudinal real-world data we need to advance our programs,” said Megan Sniecinski, Chief Operating Officer at Praxis Precision Medicines. “Our partnership represents a shared commitment to delivering better outcomes for patients and driving forward innovative ways to accelerate clinical research.”

Powering the Future of Epilepsy Research

With a proven track record, the expanded partnership now sets its sights on another area of immense unmet need: epilepsy. The collaboration will support Praxis’s ambitious ENERGY program, which is advancing the development of vormatrigine, a promising drug candidate for the treatment of epilepsy.

The ENERGY program is a multi-faceted initiative that includes the EMPOWER observational study and the POWER clinical trials. It has already attracted over 5,000 patients, demonstrating the high level of engagement within the epilepsy community. Vormatrigine itself has shown considerable potential, with Phase II results indicating a significant reduction in seizure frequency for patients with focal onset seizures. Praxis is positioning the drug as a potential first-line treatment, a goal that could transform the standard of care for millions of patients who often juggle multiple anti-seizure medications.

SEQSTER's role is to provide the technological backbone for this complex undertaking. Its platform grants Praxis automated, patient-consented access to electronic health records (EHRs) from a vast network of healthcare systems across the United States. This capability is critical for rapidly identifying and screening eligible patients for the EMPOWER and POWER studies, a process that has traditionally been a major bottleneck in clinical research. Furthermore, the platform facilitates the ongoing collection of real-world data, providing a rich, continuous stream of information on patient health and treatment outcomes outside the confines of a traditional clinic.

The Data Revolution in Clinical Trials

The synergy between Praxis, a precision neuroscience company, and SEQSTER, a health data technology firm, exemplifies a pivotal transformation in pharmaceutical R&D. The industry is moving away from siloed, episodic data collection toward a more holistic, data-driven model powered by Real-World Evidence (RWE).

SEQSTER's platform acts as a central data orchestration layer, connecting, cleaning, and standardizing health data from disparate sources into a single, unified patient view. With a regulatory-grade repository covering 150 million patients, the company offers life sciences firms an unprecedented ability to accelerate research. This approach is gaining traction as regulatory bodies like the FDA and the European Medicines Agency (EMA) increasingly recognize the value of RWE in supporting drug approvals and post-market surveillance.

“Praxis represents exactly the kind of innovative sponsor we built SEQSTER to support. One that understands the value of real-world data and is willing to rethink how clinical trials are conducted,” said Ardy Arianpour, Chief Executive Officer of SEQSTER. “We're proud to have earned their trust across multiple studies and look forward to continuing this partnership as they bring transformative therapies to patients with CNS disorders.”

By leveraging RWE, companies can design more efficient trials, enroll more representative patient populations, and gather insights that more accurately reflect a drug's performance in the real world. For complex and heterogeneous conditions like those in the CNS space, this level of data-driven insight is not just an advantage—it is becoming a necessity.

Redefining Hope for Patients

Beyond the corporate strategies and technological innovations, the core of this partnership is its potential impact on patients. For individuals living with the daily challenges of essential tremor or epilepsy, the time it takes to develop and approve a new drug can be agonizingly long. The traditional clinical trial process is often slow, expensive, and inaccessible to many.

This collaboration directly addresses these hurdles. By streamlining patient recruitment and enabling decentralized, home-based trials, the model makes participation more accessible and less burdensome. It accelerates the research timeline, potentially shaving years off the development process. For the millions of people waiting for better treatment options, this acceleration translates directly into hope.

The patient-centric focus is evident in the design of Praxis’s studies, such as the EMPOWER program, which not only gathers data for research but also provides participants with a consolidated view of their own medical records. This empowers patients to become more active participants in their own care and in the research that may one day benefit them.

As industry leaders gather here in Orlando for the SCOPE Summit, the SEQSTER-Praxis partnership stands as a compelling case study for the future of drug development. It demonstrates that by strategically combining deep scientific expertise with cutting-edge data technology, the pharmaceutical industry can create a faster, smarter, and more patient-focused path toward delivering the transformative therapies of tomorrow.